Supporting data for MAP2-mediated integrin dysregulation reprograms cancer cell plasticity to drive liver cancer cell transition to a mesenchymal and stemness state in hepatocellular carcinoma

<p dir="ltr">Our aim is to delineate how MAP2-mediated integrin dysregulation reprograms cancer cell plasticity to drive liver cancer cell transition to a mesenchymal and stemness state in hepatocellular carcinoma. Flow cytometry datasets are adopted for detecting percentage of cell apoptosis and integrin expression levels in HCC cells after MAP2 gene manipulation by CRISPR knockout and overexpression. Immunofluorescence dataset includes IF staining images of integrins, YAP, F-actin and tubulin after MAP2 gene manipulation. Immunohistochemistry dataset demonstrates MAP2 expression in HCC patients liver samples comparing to adjacent normal liver tissues. Mice experiments include images and raw data of subcutaneous injection model of HCC cells after MAP2 gene manipulation, and mice model after MAP2 drug treatment. RNA-sequencing introduces three sequencing datasets of CD133-sorted HCC mice model, Prom1-DTA HCC mice model, and HCC cells after MAP2 gene manipulation. TUNEL staining dataset includes mice liver sessions after drug treatment stained with TUNEL and Ki67, indicating cell apoptosis and proliferative cells respectively. Western blot image datasets collate all immunoblotting images of antibody stainings after MAP2 gene manipulation in MHCC97L and PLC/PRF/5 cells. </p>